What Cefadrine Treats: Main Uses and Benefits

Cefadrine is applied across domains where additional symptomatic support is needed in conditions related to susceptible bacterial infections. This medication is used in situations involving certain distressing symptoms across various body systems. It is commonly used across conditions presenting with acute episodes, including skin and soft tissue infections, upper respiratory and ear infections, and urinary tract infections.

Targeting Symptom Domains

Cefadrine is relevant for managing symptoms that interfere with daily comfort. It is applied in addressing symptom clusters that may become intense or disruptive, and is relevant for managing symptoms related to inflammatory or irritative states. This includes symptoms such as redness, swelling, and localized pain in skin infections, and the sore throat, ear pain, and fever associated with respiratory and ear conditions. When symptoms escalate temporarily, such as painful urination (dysuria) in UTIs, the medication may be part of symptomatic management, supporting patients when symptoms interfere with routine activities. It generally supports patients during episodes where symptoms create noticeable physiological strain, which assists with maintaining functional stability.

---

Quick Fact: Relief for Localized Discomfort and Systemic Symptoms	Symptom Focus	Conditions	Patient Benefit
Localized pain, swelling, and redness	Skin Infections, Abscesses	Assists with maintaining functional stability in affected areas.
Sore throat, ear pain, fever	Tonsillitis, Otitis Media	Supports patients during episodes of heightened discomfort.
Painful urination (Dysuria)	Urinary Tract Infections	Contributes to improved day-to-day comfort during symptomatic periods.

Regulatory References

1. First-Generation Cephalosporins - StatPearls - NCBI Bookshelf - NIH

Who can and cannot use Cefadrine? (Cephradine)

The population eligibility for Cefadrine is strictly defined by regulatory documents, focusing on absolute exclusions and specific population restrictions.

Absolute Contraindications The medicine is contraindicated in any patient with a known hypersensitivity to Cephradine or to the cephalosporin class of antibiotics. Due to cross-reactivity concerns, it must also be avoided in those with a history of severe immediate allergic reactions to penicillin.

Age-Related Eligibility Use is established for adults and for pediatric patients 9 months of age and older. The regulatory label states that safety has not been established for infants younger than 9 months. Older adults may require special consideration due to the potential for age-related decline in renal function.

Conditional and Restricted Use Patients with impaired renal function require specific caution and dosage adjustment because the drug is primarily eliminated by the kidneys. Use also requires caution in individuals with a history of colitis or significant gastrointestinal disease.

Pregnancy and Lactation Status Safety for Cefadrine use in human pregnancy has not been established, and use is generally avoided unless medically essential. The drug is known to be excreted into human milk, necessitating caution during lactation.

Cefadrine Interactions with other medicines and products

Official regulatory information describes Cefadrine's interaction profile through pharmacokinetic alterations and risks of cumulative toxicity.

---

Documented Pharmacokinetic and Exposure Interactions

Interacting Substance	Regulatory Description
Probenecid	Reduces the renal clearance of Cephradine by competitively inhibiting renal tubular secretion, resulting in raised serum concentrations of the antibiotic.
Zinc-Containing Supplements	Interferes with gastrointestinal absorption and may reduce the antibiotic's overall exposure.

Pharmacodynamic Interactions and Restrictions

• Loop Diuretics (e.g., Furosemide) and Nephrotoxic Drugs (e.g., Aminoglycosides) may increase the risk of nephrotoxicity (kidney damage) when co-administered.
• Cephradine may increase the anticoagulant activities of Oral Anticoagulants such as Warfarin.
• The effectiveness of Combination Oral Contraceptives may be decreased.

Timing-Based Rules and Laboratory Interference

To prevent absorption interference, Zinc-containing supplements (including multivitamins with minerals) must be administered at least three hours after the Cefadrine dose.

Additionally, Cephradine may cause a false positive result in Coombs’ testing and in certain non-enzymatic urine glucose tests (e.g., those using Benedict's or Fehling's solutions).

How Cefadrine Works: Mechanism of Action

---

Targeting Penicillin-Binding Proteins (PBPs)

The drug's mechanism initiates at the molecular level by targeting Penicillin-binding proteins (PBPs), which are essential bacterial enzymes responsible for building the rigid cell wall. The active molecule binds to these enzymes, acting as an irreversible inhibitor. This action constitutes a key mechanistic domain and leads directly to the subsequent failure of the cell's protective structure.

---

Inhibiting Peptidoglycan Cross-Linking

The inhibition of PBPs blocks the final step in the peptidoglycan synthesis pathway—the cross-linking process necessary for structural integrity. This failure results in a structurally compromised cell wall with reduced capacity to withstand the bacterial cell's high internal osmotic pressure. This mechanistic cascade culminates in osmotic lysis, triggering the cell to rupture, which is the mechanism underpinning the drug's bactericidal effect against susceptible microorganisms.

---

Mechanistic Limitations

The drug's mechanism is limited by specific biochemical resistance factors exhibited by some bacteria. The presence of β-lactamase enzymes can chemically inactivate the drug before it reaches the PBP target, while changes in the structure of the PBPs themselves can reduce the drug's binding affinity, thereby constraining the efficacy of its core mechanism.

How to Use Cefadrine

Cefadrine (Cephradine) administration is standardized across multiple dosage forms and routes. The medicine may be administered via the oral route (capsules, tablets, or reconstituted suspension) or the parenteral route (intravenous or intramuscular injection). The choice of route and form depends on the patient's clinical situation.

---

Official Dosing Principles and Regimens

Standard adult oral doses typically range from 250 mg to 500 mg per dose, with total daily intake usually divided into doses taken twice daily (q12h) or four times daily (q6h). For severe infections, the parenteral dosing regimen often involves 0.5 g to 1 g administered every 6 hours, not to exceed a total of 8 g per day. Oral forms may be taken without regard to meals.

---

Population-Specific Adjustments

Specific adjustments are utilized for certain patient groups. The pediatric dose is calculated based on body weight, generally falling within a range of 25 to 50 mg/kg/day, divided into 2 to 4 doses. Patients with renal impairment require a modified dosing schedule and reduced total daily dose, determined by their creatinine clearance. A patient may be transitioned from the injectable form to the oral form at the same dosage level once medically appropriate.

---

Treatment Duration

Therapy should not be discontinued prematurely. Administration is continued for at least 48 to 72 hours after the patient becomes asymptomatic. For infections involving Group A beta-hemolytic streptococci, a course of at least 10 days is required to mitigate the risk of late complications.

Research Evidence / Overview of Studies for Cefadrine

The research evidence for Cefadrine (Cephradine) includes Randomized Controlled Trials (RCTs) and comparative studies, often consolidated within the larger evidence base for the first-generation cephalosporin class. Research has explored Cefadrine's evaluation in clinical studies by monitoring key clinical and bacteriological outcomes.

Evidence for Use in Skin and Soft Tissue Infections

Research examining Cefadrine's evaluation in uncomplicated skin and soft tissue infections has been conducted primarily through short-term randomized controlled trials. Researchers have measured outcomes related to the resolution of localized signs like redness and swelling (referred to as 'clinical response') and the clearance of the susceptible causative bacteria (referred to as 'bacteriological response'). These studies have been evaluated in both Adults and Pediatric populations with mild-to-moderate infections.

Findings describe the observed patterns and measurements of clinical and bacteriological outcomes during the short-term study period. This evidence contributes to the broader evidence landscape for first-generation cephalosporins in this setting, resulting in a commonly applied Evidence Level categorization of High for this group. However, much of the core evidence is historical, and limited data are available specifically addressing highly drug-resistant organisms.

Evidence for Use in Urinary Tract Infections

Cefadrine was evaluated in studies concerning uncomplicated Urinary Tract Infections (UTIs). The available research includes Comparative Randomized Trials that monitored outcomes related to Clinical Cure (relief from symptoms like painful urination) and Bacteriological Cure (clearance of susceptible pathogens). The primary study populations were Adult patients presenting with acute, uncomplicated lower tract infections.

Findings describe patterns observed in these studies regarding the resolution of symptoms and the clearance of bacteria at short- to intermediate-term follow-up points. The evidence level for this indication is commonly categorized as Moderate, and the majority of research focuses exclusively on acute, simple infections. Data for certain groups, such as those with complicated or chronic UTIs, remain insufficient or have limited characterization.

Long-Term Studies and Follow-Up

The majority of research exploring Cefadrine was evaluated in contexts involving short-term or episodic symptom patterns, corresponding to the acute nature of the infections studied. Follow-up durations were typically limited to the course of therapy and a short post-treatment period to assess immediate response. Long-term outcomes are not fully established across the indications. Research provides insight into short-term changes and functional recovery but provides limited information for long-term outcomes, such as the maintenance of bacterial eradication or the durability of the observed patterns over many months or years.

Key Studies & References

1. Cephalosporins: a review (Covers generations, uses in SSTI, UTI, prophylaxis)

Common questions about Cefadrine (FAQ)

---

Q: Is it safe to drink alcohol while taking a course of Cefadrine?

A: Official regulatory information notes that combining alcohol and Cephradine may increase the risk of experiencing certain side effects. These can include effects such as dizziness or blurred vision.

---

Q: Can Cefadrine cause headaches as a side effect?

A: Headaches have been reported as a potential adverse reaction within the cephalosporin class of antibiotics, to which Cefadrine belongs. Information about any new or concerning symptoms, such as persistent or severe headaches, is typically reported to a healthcare provider.

---

Q: Is there a risk of developing antibiotic resistance if Cefadrine is used too often?

A: Official health agencies state that the use of cephalosporin antibiotics is sometimes restricted due to the concern that they could contribute to the development of resistant strains of bacteria. This is why these antibiotics are generally reserved for treating infections known to be susceptible to the drug.

---

Q: Can Cefadrine cause a metallic or unpleasant taste in the mouth?

A: Taste disorders, also known as dysgeusia, have been reported as an adverse effect associated with the cephalosporin class of antibiotics. This temporary change in taste perception can include a metallic or generally unpleasant taste.

---

Q: Does taking Cefadrine affect the effectiveness of the oral typhoid vaccine?

A: The official label notes that this class of antibiotics may interfere with the live oral typhoid vaccine. Prescribing information generally recommends that administration of the vaccine be avoided during and for a period of time after antibiotic use, as this may diminish the immune response.

---

Q: Can Cefadrine cause a mild fever or chills?

A: Fever and chills have been reported as adverse reactions associated with the cephalosporin class of antibiotics. New or worsening symptoms like fever while on therapy are commonly reviewed by a healthcare provider.

---

Q: Can Cefadrine affect blood counts like white blood cells or platelets?

A: Official product information notes that rare instances of hematological (blood-related) effects have been reported. This includes changes in white blood cell counts, such as eosinophilia and neutropenia.

---

Q: Can Cefadrine cause restlessness or hyperactivity?

A: Restlessness has been reported as a specific adverse reaction. Additionally, neurotoxicity symptoms, such as agitation, have been reported with this class of antibiotics, especially with renal impairment. These types of symptoms are generally reviewed by a healthcare provider.

---

Q: Does Cefadrine cause any issues with liver function?

A: Official information mentions that transient (temporary) increases in liver function tests (such as AST and ALT levels) have been observed with certain cephalosporins. Official labeling notes that Cefadrine should be used with caution in patients with hepatic (liver) disorders.

---

Q: Can Cefadrine treat both Gram-positive and Gram-negative bacteria?

A: Yes, Cefadrine is a first-generation cephalosporin and is active against a variety of bacteria. Official product documents confirm that Cephradine is effective against both many Gram-positive and certain Gram-negative bacteria.

---

Q: Can Cefadrine cause dizziness or affect my ability to drive?

A: Official safety advice indicates that Cefadrine may cause dizziness or blurred vision in some individuals. Due to the possibility of these effects, caution is advised when performing tasks like driving or operating heavy machinery.

---

Q: What should people with kidney problems know before taking Cefadrine?

A: Official warnings state that patients with impaired renal (kidney) function require special caution. Because Cefadrine is primarily eliminated by the kidneys, the prescribing information indicates that patients with renal impairment typically require specialized monitoring and dosage modifications.

---

Q: Can Cefadrine cause a yeast infection?

A: Regulatory documents list the adverse reaction 'vaginitis,' which is an inflammation of the vagina. While not explicitly named, this condition is frequently caused by an overgrowth of yeast (a superinfection) following antibiotic use.

---

Q: Can Cefadrine interfere with certain urine tests for sugar?

A: Yes, according to official labeling, Cefadrine may cause a false positive result when using certain non-enzymatic urine glucose tests. Examples include tests that rely on Benedict's or Fehling's solutions.

---

Q: What are the rare but serious side effects of Cefadrine?

A: While generally well-tolerated, the label specifies certain serious adverse reactions which warrant prompt medical review. These can include a severe allergic reaction (Anaphylaxis) and a serious intestinal condition known as Pseudomembranous Colitis.

---

Q: Is Cefadrine safe to use during pregnancy or while breastfeeding?

A: Official information states that safety in human pregnancy has not been established. Since the drug is known to be excreted into human milk, caution is advised during lactation.

---

Q: What kind of research has been done on the long-term effects of Cefadrine?

A: Official research summaries indicate that the majority of studies examining Cefadrine focused on short-term or episodic symptom patterns related to acute infections. Because of this, the long-term outcomes of treatment are not fully established across all indications.

Storage Conditions

Official regulatory documentation defines specific temperature requirements to maintain Cefradine's stability.

Product Form	Temperature Range	Stability/Discard Time
Unreconstituted Powder	Not exceeding 30 C	Original labeled expiry
Reconstituted Suspension	Refrigerated (2-8 C)	14 days
Reconstituted Suspension	Not exceeding 30 C	7 days

All forms must be protected from heat, sunlight, and moisture, and containers must be kept tightly closed.

Handling and Child Safety

The medication must be stored out of the reach of children, as explicitly required by governmental labeling.

Disposal Instructions

Expired or unused product must be disposed of according to local, regional, and national regulations. To protect the environment, the substance should not be released into the environment or disposed of in wastewater or drains. Patients should consult a healthcare professional for guidance on proper disposal.